PTC Therapeutics, Inc. short interest in 2026
In 2026, PTC Therapeutics, Inc.'s disclosed short interest ran from 12.82% of shares outstanding on 15 Jan 2026 to 11.67% on 15 Sep 2026, a change of -1.15 percentage points. The year's high was 21.57% on 30 Jun 2026 and its low 10.65% on 15 Apr 2026, averaging 12.81% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 12.13 days on 31 Aug 2026. Full history: PTC Therapeutics, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 12.82% (15 Jan 2026)
- End of year
- 11.67% (15 Sep 2026)
- Change
- -1.15 pp
- High
- 21.57% (30 Jun 2026)
- Low
- 10.65% (15 Apr 2026)
- Average
- 12.81%
- Highest days to cover
- 12.13 (31 Aug 2026)
- SEC filings marked
- 7
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 12.82% | 6.24 | results (8-K) |
| 30 Jan 2026 | 12.56% | 9.35 | |
| 13 Feb 2026 | 11.95% | 8.99 | |
| 27 Feb 2026 | 11.98% | 8.13 | 10-K filed, results (8-K) |
| 13 Mar 2026 | 11.02% | 6.96 | |
| 31 Mar 2026 | 11.77% | 8.41 | |
| 15 Apr 2026 | 10.65% | 10.61 | |
| 30 Apr 2026 | 12.15% | 7.44 | |
| 15 May 2026 | 12.76% | 5.99 | 10-Q filed, results (8-K) |
| 29 May 2026 | 13.29% | 11.08 | |
| 15 Jun 2026 | 14.68% | 7.82 | |
| 30 Jun 2026 | 21.57% | 5.36 | |
| 15 Jul 2026 | 12.25% | 4.75 | |
| 31 Jul 2026 | 12.66% | 7.52 | 10-Q filed, results (8-K) |
| 14 Aug 2026 | 12.25% | 10.82 | |
| 31 Aug 2026 | 11.78% | 12.13 | |
| 15 Sep 2026 | 11.67% | 11.03 |
See also: PTC Therapeutics, Inc.'s full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.